Phenindione
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
Phenindione
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| India Market Status | Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data |
| Number of Listed Products | 1 (valid: 1) |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 65045 | Dindevan 50mg Tablet (Biological E Ltd) | Strip of 10 tablets | Not stated in the licence data |
Safety Considerations
- Key warnings from the literature: Phenindione has been linked to severe immuno-allergic reactions, including acute hepatitis, acute renal failure and acute bone marrow failure. A severe drug sensitivity reaction was reported as early as 1954. Skin necrosis is a rare but occasionally lethal complication of anticoagulants of this type. Bleeding is the main complication of oral anticoagulants.
- Regulatory context: One pharmacology source states phenindione was discontinued in some markets because of a higher incidence of severe adverse effects than warfarin.
- Drug interactions: The only interaction recorded is its pharmacological target, VKORC1. No drug-drug interaction levels are available. Oral anticoagulants as a class have many clinically significant interactions (see PMID 8037888).
Package insert warnings and contraindications were not available. Please refer to the package insert for full safety information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.